- Home
- IDR vs LYEL Comparison
IDR vs LYEL Comparison
Compare IDR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | LYEL |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.6M | 490.1M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IDR | LYEL |
|---|---|---|
| Price | $38.75 | $25.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $17.50 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 256.3K | 91.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 644.44 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $25,765,373.00 | $61,000.00 |
| Revenue This Year | $55.62 | N/A |
| Revenue Next Year | $23.93 | N/A |
| P/E Ratio | $73.86 | ★ N/A |
| Revenue Growth | ★ 88.66 | N/A |
| 52 Week Low | $10.61 | $0.39 |
| 52 Week High | $54.70 | $45.00 |
Technical Indicators
Market Signals| Indicator | IDR | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 55.64 |
| Support Level | $38.13 | $21.27 |
| Resistance Level | $41.08 | $27.30 |
| Average True Range (ATR) | 2.57 | 1.78 |
| MACD | -0.12 | 0.32 |
| Stochastic Oscillator | 30.58 | 73.27 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.